Results 121 to 130 of about 1,334 (146)
Some of the next articles are maybe not open access.
Drugs, 2022
Faricimab (faricimab-svoa; Vabysmo™) is a bispecific antibody that binds to and inhibits both vascular endothelial growth factor (VEGF)-A and angiopoietin-2 (Ang-2). Administered by intravitreal injection, faricimab is being developed by Roche/Genentech for use in the treatment of retinal vascular diseases.
openaire +2 more sources
Faricimab (faricimab-svoa; Vabysmo™) is a bispecific antibody that binds to and inhibits both vascular endothelial growth factor (VEGF)-A and angiopoietin-2 (Ang-2). Administered by intravitreal injection, faricimab is being developed by Roche/Genentech for use in the treatment of retinal vascular diseases.
openaire +2 more sources
Faricimab: from research to clinical practice
Russian Annals of Ophthalmology, 2023Development of new molecules for anti-angiogenic therapy pursues the following objectives: to increase the interval between injections, which can reduce the treatment burden; to improve the effectiveness of treatment by affecting various links of pathogenesis; to ensure a good safety profile.
Yu.N. Yusef +2 more
openaire +2 more sources
Choroidal Detachment After Intravitreal Injection of Faricimab
JAMA Ophthalmology, 2023This case report discusses a diagnosis of choroidal detachment and suprachoroidal hemorrhage in a patient aged 70 years after an uneventful intravitreal injection of faricimab for neovascular age-related macular degeneration.
Etienne M, Schönbach +1 more
openaire +2 more sources
Canadian Journal of Health Technologies, 2022
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments ...
openaire +1 more source
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments ...
openaire +1 more source
Faricimab-Associated Retinal Vasculitis
Journal of VitreoRetinal DiseasesPurpose: To report a case of retinal vasculitis after intravitreal faricimab-svoa injection. Methods: A case and its management were reviewed. Results: A 77-year-old woman presented with a painless decrease in visual acuity (VA) to counting fingers after receiving an intravitreal faricimab-svoa injection for neovascular age-related macular ...
Mohammad Z. Siddiqui +2 more
openaire +2 more sources
Severe Intraocular Inflammation Following Intravitreal Faricimab
JAMA OphthalmologyImportanceMonitoring for and reporting potential cases of intraocular inflammation (IOI) in clinical practice despite limited occurrences in clinical trials, including experiences with relatively new intravitreal agents, such as brolucizumab, pegcetacoplan, or faricimab, helps balance potential benefits and risks of these agents.ObjectiveTo provide ...
Loka, Thangamathesvaran +7 more
openaire +2 more sources
Inflammation and Occlusive Retinal Vasculitis Post Faricimab
JAMA OphthalmologyImportanceRandomized clinical trials have shown the safety and efficacy of faricimab as a novel vascular endothelial growth factor and angiopoietin-2 inhibitor in the treatment of neovascular age-related macular degeneration (nAMD) and macular edema of various etiologies.
Will, Bruening +4 more
openaire +2 more sources
Dosing vs Assessment Intervals With Faricimab and Aflibercept
JAMA OphthalmologyThis Viewpoint highlights the discrepancy between dosing and patient assessment schedules in clinical trials for 2 new intravitreal agents, faricimab, 6 mg, and aflibercept, 8 mg, to treat neovascular age-related macular degeneration.
K Bailey, Freund +2 more
openaire +2 more sources
Canadian Journal of Health Technologies
Canada’s Drug Agency (CDA-AMC) recommends that Vabysmo be reimbursed by public drug plans for the treatment of macular edema secondary to retinal vein occlusion (RVO) if certain conditions are met. Vabysmo should be covered to treat patients with macular edema secondary to RVO provided that it is covered for a similar patient population to other ...
openaire +1 more source
Canada’s Drug Agency (CDA-AMC) recommends that Vabysmo be reimbursed by public drug plans for the treatment of macular edema secondary to retinal vein occlusion (RVO) if certain conditions are met. Vabysmo should be covered to treat patients with macular edema secondary to RVO provided that it is covered for a similar patient population to other ...
openaire +1 more source